<?xml version='1.0' encoding='utf-8'?>
<document id="26927160"><sentence text="Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions." /><sentence text="Venetoclax (ABT-199) represents a specific B-cell lymphoma 2 (Bcl-2) inhibitor that is currently under development for the treatment of lymphoid malignancies" /><sentence text=" So far, there is no published information on its interaction potential with important drug metabolizing enzymes and drug transporters, or its efficacy in multidrug resistant (MDR) cells" /><sentence text=" We therefore scrutinized its drug-drug interaction potential in vitro" /><sentence text=" Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits" /><sentence text=" Inhibition of drug transporters (P-glycoprotein (P-gp, ABCB1), breast cancer resistance protein (BCRP), and organic anion transporting polypeptides (OATPs)) was evaluated by the use of fluorescent probe substrates" /><sentence text=" Induction of drug transporters and drug metabolizing enzymes was quantified by real-time RT-PCR" /><sentence text=" The efficacy of venetoclax in MDR cells lines was evaluated with proliferation assays" /><sentence text=" Venetoclax moderately inhibited P-gp, BCRP, OATP1B1, OATP1B3, CYP3A4, and CYP2C19, whereas CYP2B6 activity was increased" /><sentence text=" Venetoclax induced the mRNA expression of CYP1A1, CYP1A2, UGT1A3, and UGT1A9" /><sentence text=" In contrast, expression of ABCB1 was suppressed, which might revert tumor resistance towards antineoplastic P-gp substrates" /><sentence text=" P-gp over-expression led to reduced antiproliferative effects of venetoclax" /><sentence text=" Effective concentrations for inhibition and induction lay in the range of maximum plasma concentrations of venetoclax, indicating that it might act as a perpetrator drug in pharmacokinetic drug-drug interactions" /><sentence text=" " /></document>